The incorporation of somatotropic axis hormone supplementation, particularly low dose IGF-1, as a pharmacological therapy in patients with the triad of NAFLD, insulin-resistance and sarcopenia could be promising. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.